Conavi Medical, a company focused on imaging tech to guide minimally invasive cardiovascular procedures, has revealed strategic leadership changes related to its planned commercial launch and expansion in the U.S.
The company submitted its next-gen Novasight Hybrid IVUS/OCT intravascular imaging system to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. It’s building the infrastructure needed for a successful U.S. launch.
Conavi appointed Mark Quick as chief financial officer (CFO). He will oversee financial strategy and investor engagement as the company prepares for U.S. launch.